Karyopharm extends indenture forbearance period again, now to Nov 1, 2026 from Oct 22

Karyopharm Therapeutics Inc.

Forbearance Period under the Forbearance Agreement and Limited Waiver to Indentures dated September 10, 2026 now ends 11:59 p.m. Eastern on November 1, 2026, instead of October 22, 2026.
Extension was made under Section 19 of the Forbearance Agreement by the applicable parties; no other terms or new consideration disclosed.
Second disclosed extension: prior 8-Ks on September 11, 2026 and October 14, 2026 covered the original agreement and the first push-out of the forbearance date.
Signing officer: Michael Mano, Executive Vice President, Chief Legal Officer and Secretary; company based in Newton, Massachusetts; stock symbol KPTI on Nasdaq.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.